| Literature DB >> 36157464 |
Kan Sun1, Xianchao Xiao2, Lili You1, Xiaosi Hong1, Diaozhu Lin1, Yujia Liu2, Chulin Huang1, Gang Wang2, Feng Li1, Chenglin Sun2, Chaogang Chen3, Jiahui Lu3, Yiqin Qi1, Chuan Wang1, Yan Li1, Mingtong Xu1, Meng Ren1, Chuan Yang1, Guixia Wang2, Li Yan1.
Abstract
A tool was constructed to assess need of an oral glucose tolerance test (OGTT) in patients whose fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are normal. Data was collected from the longitudinal REACTION study conducted from June to November 2011 (14,686 subjects, aged ≥ 40 y). In people without a prior history of diabetes, isolated high 2-hour plasma glucose was defined as 2-hour plasma glucose ≥ 11.1 mmol/L, FPG < 7.0 mmol/L, and HbA1c < 6.5%. A predictive nomogram for high 2-hour plasma glucose was developed via stepwise logistic regression. Discrimination and calibration of the nomogram were evaluated by the area under the receiver operating characteristic curve (AUC) and Hosmer-Lemeshow test; performance was externally validated in Northeast China. Parameters in the model included gender, age, drinking status, marriage status, history of hypertension and hyperlipidemia, waist-to-hip ratio, FPG, and HbA1c. All variables were noninvasive, except FPG and HbA1c. The AUC of the nomogram for isolated high 2-hour plasma glucose was 0.759 (0.727-0.791) in the development dataset. The AUCs of the internal and externally validation datasets were 0.781 (0.712-0.833) and 0.803 (0.778-0.829), respectively. Application of the nomogram during the validation study showed good calibration, and the decision curve analysis indicated that the nomogram was clinically useful. This practical nomogram model may be a reliable screening tool to detect isolated high 2-hour plasma glucose for individualized assessment in patients with normal FPG and HbA1c. It should simplify clinical practice, and help clinicians in decision-making.Entities:
Keywords: 2h OGTT; diabetes mellitus; hyperglycemia; nomogram model; risk assessment model
Mesh:
Substances:
Year: 2022 PMID: 36157464 PMCID: PMC9492843 DOI: 10.3389/fendo.2022.943750
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1Flow chart of the selection of the research participants.
Characteristics of participants in the Guangzhou and Changchun datasets in China; without and with isolated high 2-hour plasma glucose.
| Guangzhou | Changchun | |||||
|---|---|---|---|---|---|---|
| No | Yes* |
| No | Yes* |
| |
| Subjects, n | 7509 | 332 | 6556 | 289 | ||
| Age, y | 55.16 ± 7.64 | 58.62 ± 9.89 | <0.001 | 56.85 ± 9.77 | 61.36 ± 10.17 | <0.001 |
| Male | 2099 (27.95) | 109 (32.83) | 0.0613 | 2070 (31.57) | 118 (40.83) | 0.001 |
| Family history of DM | 1140 (15.19) | 59 (17.78) | 0.228 | 754 (11.50) | 33 (11.42) | 1.000 |
| Current smoking | 745 (9.92) | 40 (12.05) | 0.416 | 908 (13.85) | 45 (15.57) | 0.703 |
| Current drinking | 246 (3.28) | 22 (6.63) | 0.003 | 557 (8.50) | 38 (13.15) | 0.018 |
| Married or cohabitating | 6801 (90.57) | 283 (85.24) | 0.005 | 6051 (92.30) | 267 (92.39) | 0.709 |
| Hypertension history | 997 (13.28) | 86 (25.90) | <0.001 | 1051 (16.03) | 90 (31.14) | <0.001 |
| Hyperlipidemia history | 461 (6.14) | 41 (12.35) | <0.001 | 422 (6.44) | 34 (11.76) | <0.001 |
| SBP, mmHg | 124.11 ± 15.27 | 131.40 ± 16.56 | <0.001 | 138.43 ± 21.53 | 148.85 ± 21.87 | <0.001 |
| DBP, mmHg | 74.77 ± 9.51 | 77.16 ± 9.79 | <0.001 | 79.95 ± 11.94 | 82.91 ± 11.77 | <0.001 |
| Height, cm | 158.39 ± 7.40 | 157.74 ± 7.07 | 0.103 | 161.43 ± 7.58 | 161.01 ± 7.67 | 0.366 |
| Weight, kg | 58.56 ± 9.11 | 59.00 ± 9.25 | 0.395 | 64.69 ± 10.78 | 66.35 ± 11.31 | 0.015 |
| BMI, kg/m2 | 23.29 ± 2.96 | 23.68 ± 3.19 | 0.033 | 24.76 ± 3.29 | 25.53 ± 3.59 | <0.001 |
| WC, cm | 80.59 ± 8.72 | 82.49 ± 9.46 | <0.001 | 83.01 ± 9.26 | 86.17 ± 8.23 | <0.001 |
| Hipline, cm | 93.60 ± 6.50 | 93.57 ± 6.98 | 0.933 | 96.91 ± 6.92 | 98.47 ± 6.73 | <0.001 |
| WHR | 0.86 ± 0.06 | 0.88 ± 0.06 | <0.001 | 0.86 ± 0.06 | 0.87 ± 0.05 | <0.001 |
| FPG, mmol/L | 5.13 ± 0.57 | 5.78 ± 0.65 | <0.001 | 5.47 ± 0.53 | 5.98 ± 0.56 | <0.001 |
| HbA1c,% | 5.79 ± 0.35 | 5.97 ± 0.32 | <0.001 | 5.67 ± 0.38 | 5.94 ± 0.35 | <0.001 |
| Physical activity (MET-h/week) | 21.0[10.5, 45.0] | 21.0[9.0, 43.0] | 0.185 | 21.0[0.0, 42.0] | 20.0[0.0, 31.5] | 0.371 |
| Prevalence of metabolic syndrome (%) | 1120 (16.25) | 101 (30.42) | <0.001 | 1731 (26.40) | 152 (52.60) | <0.001 |
| Prevalence of hypertension (%) | 1843 (24.54) | 146 (43.98) | <0.001 | 3122 (47.62) | 198 (68.51) | <0.001 |
| Prevalence of dyslipidemia (%) | 5392 (71.81) | 269 (81.02) | <0.001 | 4225 (64.44) | 217 (75.09) | <0.001 |
*Without (no) and with (yes) isolated high 2-hour plasma glucose. Guangzhou and Changchun datasets are n = 7841 and n = 6845, respectively. Data are reported as n (%) for categorical variables and mean ± SD or median (interquartile ranges) for skewed variables. The P-value is derived from the univariable association analyses between each of the characteristics and isolated high 2-hour plasma glucose.
Risk of factors for isolated high 2-hour plasma glucose in the development dataset 1.
| Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|
| β | OR (95% CI) |
| β | OR (95% CI) |
| |
| Intercept | -10.178 | — | <0.001 | -20.543 | — | <0.001 |
| Age | 0.029 | 1.03 (1.01, 1.05) | <0.001 | 0.020 | 1.02 (1.00, 1.04) | 0.020 |
| Female | 0.051 | 1.05 (0.78, 1.44) | 0.745 | 0.049 | 1.05 (0.77, 1.44) | 0.757 |
| Drinking status | 0.056 | 1.06 (0.81, 1.36) | 0.669 | 0.041 | 1.04 (0.79, 1.35) | 0.762 |
| Marriage status | 0.134 | 1.15 (0.92, 1.41) | 0.203 | 0.139 | 1.15 (0.92, 1.42) | 0.209 |
| Hypertension history | 0.410 | 1.51 (1.08, 2.07) | 0.013 | 0.395 | 1.48 (1.06, 2.06) | 0.019 |
| Hyperlipidemia history | 0.331 | 1.39 (0.90, 2.07) | 0.117 | 0.271 | 1.31 (0.84, 1.97) | 0.210 |
| SBP | 0.018 | 1.02 (1.01, 1.03) | <0.001 | 0.012 | 1.01 (1.00, 1.02) | 0.011 |
| WHR2 | 0.032 | 1.03 (1.01, 1.05) | 0.004 | 0.020 | 1.02 (1.00, 1.04) | 0.072 |
| Physical activity (MET-h/week) | -0.002 | 1.00 (0.99, 1.00) | 0.240 | -0.003 | 1.00 (0.99, 1.00) | 0.114 |
| FPG | NA | NA | NA | 1.001 | 2.72 (2.16, 3.43) | <0.001 |
| HbA1c | NA | NA | NA | 1.232 | 3.43 (2.21, 5.39) | <0.001 |
| C-index datasets | ||||||
| Development | 0.676 (0.641-0.711) | 0.759 (0.727-0.791) | ||||
| Internal validation | 0.664 (0.602-0.726) | 0.773 (0.712-0.833) | ||||
| External validation | 0.686 (0.655-0.716) | 0.803 (0.778-0.829) | ||||
1β is the regression coefficient. Participant without (with) isolated high 2-hour plasma glucose was defined as 0 (1).
2Increasing for 0.01 units. NA, Not Available.
Figure 2Nomogram for participants with isolated high 2-hour plasma glucose.
Figure 3Nomogram performance for assessing the rate of isolated high 2-hour plasma glucose. (A) Development dataset. (B) Internal validation dataset. (C) External validation dataset.
Figure 4Calibration curves of the nomogram for rates of isolated high 2-hour plasma glucose in the validation datasets. (A) Development datasets (Guangzhou). (B) Internal validation datasets (Guangzhou). (C) External validation datasets (Changchun). The curves represent calibration of each model in terms of agreement between the assessed risk and observed outcomes of isolated.
Figure 5Decision curve analysis for the nomogram model in the development and internal and external validation datasets.